Jia Yongheng, Liu Xianjun, Liu Can, Wang Jialin, Shen Qiming, Lu Keyu, Meng Xianglong, Li Hao, Fang Xuedong, Xu Zhonghang
Department of Gastrointestinal Colorectal and Anal Surgery, The China-Japan Union Hospital of Jilin University, No. 126 Xian Tai Street, Changchun, 130000, China.
College of Biological and Food Engineering, Jilin Engineering Normal University, No. 3050 Kaixuan Street, Changchun, 130000, China; Postdoctoral Research Workstation, Changchun Gangheng Electronics Company Limited, Changchun, 130000, China.
J Ethnopharmacol. 2025 Sep 1;354:120511. doi: 10.1016/j.jep.2025.120511.
In traditional Chinese medicine (TCM), Curcuma longa L. has been used since ancient times to treat chest and abdominal distending pain caused by cold coagulation, qi stagnation, and blood stasis, as well as cold-bi syndrome shoulder-arm pain. Colorectal cancer (CRC) falls under the categories of "Jiju" (Mass Accumulation) in TCM. The core pathogenesis involves spleen deficiency, dampness-toxin accumulation, and blood stasis, which are closely related to qi circulation stagnation, blood stasis, and phlegm coagulation. Curcuma longa L. is pungent and warm in nature, with the effects of "breaking blood to eliminate masses and promoting qi to resolve stagnation". Curcumin, a polyphenolic compound, is the main pharmacological component extracted from the rhizomes of Curcuma longa L. Modern pharmacological studies have found that curcumin exhibits multiple pharmacological activities, including anti-inflammatory, anti-tumor, anti-angiogenic, anti-metastatic, and anti-multidrug resistance effects.
This study aimed to evaluate the efficacy of curcumin in animal models of colorectal cancer and explore its mechanism of action.
Databases including Embase, Web of Science, PubMed, China National Knowledge Infrastructure, and Wanfang Database were searched from their inception to March 2025. The primary outcomes were reduction in tumor volume and weight, with subgroup analyses additionally conducted.
The analysis included 22 studies involving 536 animals. The results of the studies showed that Curcumin administration resulted in a significant reduction in tumor volume and a decrease in tumor weight relative to controls. In addition, the combination of Curcumin and chemotherapeutic agents had a synergistic effect, significantly reduced the volume and weight of CRC tumors relative to chemotherapeutic agents alone. Subgroup analyses showed that the efficacy of the oral route of Curcumin administration was superior to that of other routes of administration. Dose-response analysis suggested that the optimal dose range of Curcumin was 25-50 mg/kg/day and the duration of intervention was 14-21 days.
Curcumin can significantly inhibit the growth of CRC, attributed to its various anticancer properties such as modulation of intestinal microbes, alleviation of intestinal inflammation, inhibition of tumor cell proliferation, promotion of apoptosis, inhibition of metastasis, and sensitization to chemotherapy. However, clinical trials are still needed to evaluate the efficacy of Curcumin in humans.
在传统中医（TCM）中，姜黄自古以来就被用于治疗因寒凝、气滞和血瘀引起的胸腹胀痛，以及寒痹证肩臂疼痛。结直肠癌（CRC）在中医中属于“积聚”范畴。其核心病机涉及脾虚、湿毒积聚和血瘀，这与气滞、血瘀和痰凝密切相关。姜黄性辛温，具有“破血逐瘀、行气止痛”之功效。姜黄素是从姜黄根茎中提取的主要药理成分，是一种多酚类化合物。现代药理学研究发现，姜黄素具有多种药理活性，包括抗炎、抗肿瘤、抗血管生成、抗转移和抗多药耐药作用。
本研究旨在评估姜黄素在结直肠癌动物模型中的疗效，并探讨其作用机制。
检索了Embase、Web of Science、PubMed、中国知网和万方数据库，检索时间从建库至2025年3月。主要结局指标为肿瘤体积和重量的减小，并进行了亚组分析。
分析纳入22项研究，涉及536只动物。研究结果表明，与对照组相比，给予姜黄素可显著减小肿瘤体积并降低肿瘤重量。此外，姜黄素与化疗药物联合使用具有协同作用，相对于单独使用化疗药物，可显著减小CRC肿瘤的体积和重量。亚组分析表明，姜黄素口服给药途径的疗效优于其他给药途径。剂量反应分析表明，姜黄素的最佳剂量范围为25 - 50mg/kg/天，干预持续时间为14 - 21天。
姜黄素可显著抑制CRC的生长，这归因于其多种抗癌特性，如调节肠道微生物、减轻肠道炎症、抑制肿瘤细胞增殖、促进细胞凋亡、抑制转移以及对化疗的增敏作用。然而，仍需要进行临床试验来评估姜黄素在人体中的疗效。
